Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer

Overview of attention for article published in Breast Cancer Research, March 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (75th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 15 X users

Citations

dimensions_citation: 34 Dimensions

Readers on

mendeley: 68 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 34 publications that cite this research output.

34

The most recent citing publications are shown below. View all 34 publications that cite this research output on Dimensions.

Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models

Article in Drug Resistance Updates (March 2024)

PDGFRα/β heterodimer activation negatively affects downstream ERK1/2 signaling and cellular proliferation

Preprint in bioRxiv (December 2023)

Eph receptors and ephrins in cancer progression

Article in Nature Reviews Cancer (November 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.